The mission of our generics business is to make healthcare more affordable and to improve access to important medicines through the provision of high-quality small-molecule generics to patients all around the world. Currently our products are approved by regulatory agencies in around 100 countries and marketed through strategic partnerships and - in dedicated areas - through direct sales.

Innovative excellence

Complex small-molecule generics and hybrids form the backbone of our product portfolio. Our generic product range covers many therapeutic areas with medicines to treat a large number of diverse indications. One common factor drives our business and that is the pursuit of innovative excellence with a clear preference for complex synthesis and sophisticated dosage forms. This results in first-rate medicines that meet market needs, supported by strong patents that guarantee a long product lifespan. Our products are marketed at the earliest possible opportunity and sold at competitive prices.

Strategy

Synthon’s strategy from its inception included the development of a vertically integrated organization for small-molecule generics, controlling every facet of the development chain beginning with research, development and production of active pharmaceutical ingredients through to manufacture and sale of our drug products.

 Our generic pipeline is well-filled with research projects and pending regulatory applications.

At-work-Synthon-Czech-Republic-3-002e4bfe.jpg
About generic medicines

Generic medicines (or: generics) are fully equivalent to the originator product in strength, route of administration, quality and performance characteristics, and intended use.

read more
At-work-Synthon-Czech-Republic-2-8bb5f2ce.jpg
Glatiramer

In 2016, Synthon successfully concluded the decentralized procedures for glatiramer acetate 20 mg/mL, a therapeutically equivalent version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS) in Europe.

read more
Adverse events

If you experience any side effects associated with a Synthon product, we need to get in touch with you for further information. Please contact us to report an adverse event related to Synthon products by sending us an e-mail.

report adverse event

Press releases
05 Oct 2017

Regulatory Approval in Europe granted for Synthon’s glatiramer acetate 40 mg/ml

read more
13 Sep 2017

European Patent Office decides in Synthon’s favor in glatiramer patent case

read more
Events
09 Oct 2018 - 11 Oct 2018 - IFEMA, Feria de Madrid, Spain

CPhI Worldwide 2018

The world’s leading pharmaceutical platform

read more